IPP Bureau
Aster DM Healthcare gets shareholders nod to separate the GCC business
By IPP Bureau - January 24, 2024
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Lupin receives tentative USFDA approval for Rivaroxaban Tablets USP
By IPP Bureau - January 24, 2024
Cipla posts Q3 FY24 consolidated PAT at Rs. 1,055.90 Cr
By IPP Bureau - January 23, 2024
Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023
Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat
By IPP Bureau - January 23, 2024
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome
By IPP Bureau - January 23, 2024
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis
By IPP Bureau - January 23, 2024
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr
By IPP Bureau - January 23, 2024
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr
By IPP Bureau - January 23, 2024
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
AstraZeneca Pharma India receives permission to import new drug
By IPP Bureau - January 22, 2024
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Tatva Chintan Pharma Chem Q3 FY24 consolidated PAT drops to Rs. 3.45 Cr
By IPP Bureau - January 22, 2024
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
Novo Holdings expands portfolio in cancer diagnostics
By IPP Bureau - January 22, 2024
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Thermo Fisher receives AIFA’s GMP approval for manufacturing facility of RNA-based products in Italy
By IPP Bureau - January 22, 2024
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Shilpa Medicare receives Europe approval for Amifampridine Tablets, 10 mg
By IPP Bureau - January 20, 2024
This product has sales of about US$ 20 million in Europe
AbbVie launches Produodopa for treatment of parkinson's disease in EU
By IPP Bureau - January 20, 2024
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market
By IPP Bureau - January 19, 2024
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
